Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:IMNM News 15 December 2025 - 9 January 2026

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

New York, January 9, 2026, 13:01 EST — Regular session Immunome, Inc. shares jumped on Friday, outpacing a firmer biotech tape. The Nasdaq-listed stock (IMNM) was up 7.4% at $21.97, after trading between $20.71 and $22.00. The move keeps attention on Immunome’s lead drug, varegacestat, being developed for desmoid tumors — non-cancerous growths in connective tissue that can still be painful and hard to treat. The company has said it plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration in the second quarter of 2026; an NDA is the formal request for approval to
9 January 2026
·······
Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

NEW YORK, Jan 5, 2026, 15:54 EST — Regular session Shares of Immunome, Inc. fell 5.3% to $19.72 in late afternoon trading on Monday, underperforming U.S. biotech peers. The SPDR S&P Biotech ETF slid 1.1% and the iShares Nasdaq Biotechnology ETF was off 0.9%. IMNM opened at $20.83 and touched $19.36, with about 1.6 million shares changing hands by 3:54 p.m. EST, according to market data. Immunome has not posted a news release since Dec. 16, when it priced a public offering of common stock, the company’s investor relations site showed. That quiet calendar can magnify day-to-day swings in small-cap
5 January 2026
·····
Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

December 15, 2025 — Immunome, Inc. (NASDAQ: IMNM) is having the kind of biotech day that traders circle in red ink: a major clinical trial win, a sharp move in the share price, and a fast-rising debate over what “best-in-class” might be worth if regulators agree. The catalyst is Immunome’s positive topline Phase 3 RINGSIDE results for varegacestat (formerly AL102) in progressing desmoid tumors—a rare, non-metastatic but often aggressive disease that can cause severe pain and disability. Reuters reported the news pushed the stock up 34.3% in premarket trading Monday. Reuters By mid-session, IMNM remained strongly higher. As of 14:46
15 December 2025
·····

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop